
PFNX
Healthcare · Biotechnology · $437.3M market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Sep 30, 2020
EPS trend, 90 days to now · +10.7% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Aug 6, 2020 | Time not confirmed | -0.28 | -0.30 | -7.1% |
| May 7, 2020 | Time not confirmed | -0.24 | -0.31 | -29.2% |
| Mar 11, 2020 | Time not confirmed | 0.16 | 0.29 | +81.3% |
| Nov 7, 2019 | Time not confirmed | -0.04 | 0.09 | +325.0% |
| Aug 8, 2019 | Time not confirmed | -0.31 | -0.24 | +22.6% |
| May 9, 2019 | Time not confirmed | -0.26 | -0.12 | +53.8% |
| Mar 11, 2019 | Time not confirmed | -0.35 | -0.22 | +37.1% |
| Nov 7, 2018 | Time not confirmed | -0.33 | -0.34 | -3.0% |
| Aug 8, 2018 | Time not confirmed | -0.36 | -0.41 | -13.9% |
| May 10, 2018 | Time not confirmed | -0.43 | -0.47 | -9.3% |
| Mar 15, 2018 | Time not confirmed | 0.12 | 0.23 | +91.7% |
Pfenex Inc., a clinical-stage development and licensing biotechnology company, focuses on developing protein therapies for unmet patient needs. Its lead product candidate include PF708, a therapeutic equivalent drug candidate to Forteo (teriparatide) for the treatment of osteoporosis. The company also develops PF743, a recombinant crisantaspase; PF745, a recombinant crisantaspase with half-life extension…